Featured Stories

Harnessing the unmatched specificity of padlock probe chemistry in combination with isothermal amplification and an optical readout, Helios™ can simultaneously detect hundreds to thousands of targets at single-copy sensitivity levels.

Hyperion Biosystems and Colorcon today announced a licensing agreement to commercialize and market a jointly-developed, anti-counterfeiting technology for solid oral dosage pharmaceutical and nutraceutical products.

Hyperion Biosystems announces the appointment of Dr. Kevin Ban as a strategic advisor to its Board of Directors effective June 1, 2024.

Hyperion Biosystems announces Dr. Michael Mina, MD, Ph.D., joins its Board of Directors as an independent director effective May 24, 2024.

Hyperion Biosystems and Princeton BioMeditech announced they secured a second NIH award.

Hyperion Biosystems. has published a paper demonstrating that smartphone-based luminescence imaging can be a promising tool for time-gated measurements.

The funds will be used to accelerate commercialization of a version of PBM’s Status™ COVID-19/Flu A&B antigen test used in conjunction with C2Sense’s Halo diagnostic reader.

Hyperion Biosystems, today announced that its Board of Directors has appointed Jim Mahoney, MBA, MMA as an independent director effective January 31, 2023.

Hyperion Biosystems, announced Adam Behrens, Ph.D., joins its Board of Directors as an independent director effective January 31, 2023.

Hyperion Biosystems, today announced the appointment of the Honorable Andrew Weber to its Board of Directors effective January 31, 2023.

Digital innovation and connected diagnostics can help address global health issues but health governance must advance with new tech.

Hyperion Biosystems announced the successful closing of its $8M Series B financing round with participation from new and existing investors.